Publications by authors named "T J Wilkinson"
Introduction: Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors (≥12 years). It is also indicated for perioperative care in the same patient population in Europe and the United Kingdom.
Aim: To assess the incidence of rebleeding and review treatment outcomes in subjects with haemophilia with inhibitors enrolled in the phase 3 PERSEPT 1 clinical trial.
Interleukin (IL)-33 is released following tissue damage, causing airway inflammation and remodelling via reduced IL-33 (IL-33)/serum stimulation-2 (ST2) and oxidised IL-33 (IL-33)/receptor for advanced glycation end products (RAGE)/epidermal growth factor receptor (EGFR) pathways. This study aimed to identify associations of IL-33 with clinical outcomes and pathological mechanisms during viral lower respiratory tract disease (LRTD). Ultra-sensitive immunoassays were developed to measure IL-33, IL-33 and IL-33/sST2 complexes in samples from patients hospitalised with COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- Weight loss can inadvertently lead to a decrease in both lean and fat tissue, potentially causing individuals, even younger ones, to become frail rather than just improving their body composition.
- This systematic review will evaluate the impact of nutritional supplements on maintaining lean mass during weight loss, particularly when exercise isn't an option.
- The findings will follow PRISMA standards and will be published in a peer-reviewed journal, marking a significant contribution to understanding nutritional support during weight loss.